A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
GQ1001 is well tolerated and shows promising efficacy in previously treated HER2-positive advanced solid tumors. DRDE was determined as 8.4 mg/kg for following trials. Trial registration NCT, NCT04450732, Registered 23 June 2020, https://clinicaltrials.gov/study/NCT04450732.
Authors
- Gary Richardson (ORCID: https://orcid.org/0000-0003-2122-8285)
- Yan Shi (ORCID: https://orcid.org/0000-0001-7421-3306)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Charlotte Lemech (ORCID: https://orcid.org/0000-0002-5399-9431)
- Xianbao Zhan
- Christina T. Teng (ORCID: https://orcid.org/0000-0002-3716-8611)
- Chenfei Zhou (ORCID: https://orcid.org/0000-0002-9760-3216)
- Ashanya Malalasekera (ORCID: https://orcid.org/0000-0003-1697-5825)
- Hui Yang (ORCID: https://orcid.org/0000-0002-8023-0230)
- Bin Wang (ORCID: https://orcid.org/0000-0002-4467-4176)
- Wei Wang (ORCID: https://orcid.org/0000-0001-5161-8175)
- Yajun Sun
- Jieqiong Liu
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Sun Yat-sen University (CN)
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- UNSW Sydney (AU)
- Cabrini Hospital (AU)
- Sun Yat-sen Memorial Hospital (CN)
- Changhai Hospital (CN)
- Sydney Local Health District (AU)
- South Western Sydney Local Health District (AU)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1186/s12967-024-05985-z
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09